Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
Quantum BioPharma (NASDAQ: QNTM) has received a Product License (PN 80144141) from Health Canada for Qlarity™, its innovative natural health product.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Quantum BioPharma (NASDAQ: QNTM) has received a Product License (PN 80144141) from Health Canada for Qlarity™, its innovative natural health product. The license allows Quantum to market Qlarity in Canada with approved claims for enhancing energy production, metabolism, mental alertness, and cognitive performance.
The company has already licensed a similar product in the United States under the brand name unbuzzd™. This regulatory approval marks a significant milestone in Quantum's strategy to expand its portfolio of innovative biotech solutions for neurodegenerative and metabolic disorders.
Positive
- Received Health Canada Product License approval for Qlarity™
- Expands market presence into Canada
- Product already licensed in US market under unbuzzd™ brand
- Multiple approved health claims for energy, metabolism, and cognitive performance
Negative
- None.
Details
News Market Reaction – QNTM
On Sep 18, the day this news came out, QNTM closed 12.49% above the previous close.
Data tracked by StockTitan Argus for the Sep 18 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. Quantum licensed a similar product, as a dietary supplement, for sale in the United States under the brand name unbuzzd™ (unbuzzd.com). This Product License from Health Canada permits Quantum to sell Qlarity in Canada.
Health Canada’s product license permits the following recommended uses of Qlarity, among others: helps in energy production and metabolism; helps to maintain/support normal electrolyte balance; helps (temporarily) to enhance (physical) energy and motor performance, reduce fatigue, promote endurance, promote mental alertness, and enhance cognitive performance.
“This is a milestone in Quantum BioPharma’s mission to bring innovative products to the market”, said Mr. Zeeshan Saeed, CEO of Quantum BioPharma. “We can now sell Qlarity to the Canadian market, leveraging its significant potential to improve consumer well-being.”
“I am delighted that the Natural Health Products Directorate at Health Canada has provided a Product License for Qlarity”, said Professor Lakshmi P. Kotra, a board director at Quantum BioPharma, a professor of medicinal chemistry at University of Toronto, and a senior scientist at the Krembil Research Institute, University Health Network. “I look forward to the launch of Qlarity in Canada, offering a solution to support energy, metabolism, mental alertness and cognitive performance”.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
For more information visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma’s filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.